This article needs additional citations for verification. (December 2009) (Learn how and when to remove this template message)
|President and CEO||Dario C. Altieri, M.D.|
|Address||3601 Spruce Street, Philadelphia, PA 19104, United States|
The Wistar Institute is an independent, nonprofit research institution and an international leader in biomedical science, with special expertise in oncology, immunology, infectious disease and vaccine research. Located in the University City section of Philadelphia, Wistar was founded in 1892 as America's first nonprofit institution solely focused on biomedical research and training.
Since 1972, Wistar has been a National Cancer Institute (NCI)-designated Cancer Center and its application for renewal of the Cancer Center Support Grant received the highest rating of "exceptional" in two consecutive terms in 2013 and 2018.
Known worldwide for vaccine development, some of the Institute's accomplishments are its contributions to the creation of vaccines for rubella (German Measles), rotavirus and rabies.
Work at The Wistar Institute Cancer Center spans from basic to translational and disease-relevant cancer research with focus on prevention, diagnosis and treatment. The Center is organized in three research programs:
- Gene Expression and Regulation Program, focusing on cancer genomics and epigenetics
- Immunology, Microenvironment and Metastasis Program, focusing on the role of the tumor microenvironment and the immune system in tumor progression and response to therapy
- Molecular and Cellular Oncogenesis Program, focusing on the molecular and cellular events underlying cancer development and the role of tumor cell metabolism in metastatic competence
Wistar also maintains one of the largest melanoma research programs in the U.S. outside of the NIH.
Cancer research accomplishments:
- Identification of genetic alterations linked to the development of blood cancer, paving the way for the later development of molecular therapies.
- Pioneering the monoclonal antibody technology and its development for clinical use.
- Discovery of molecular markers for non-invasive diagnostic tests for lung cancer and cutaneous T-cell lymphoma, currently in clinical development.
- Advancements in melanoma biology and understanding the molecular pathways that drive tumor development, with the creation of a Wistar melanoma cell line repository that is one of the largest and most used in the world, with more than 500 cell lines.
Immunology and vaccine development
The Wistar Institute is a global leader in vaccine development. The Wistar Vaccine & Immunotherapy Center advances new generation DNA-based technologies for prevention of infectious diseases and for cancer immunotherapy.
The HIV-1 research program at Wistar is co-leading a consortium of 30 of the nation's top HIV investigators, which in 2016 received a nearly $23 million grant from the National Institutes of Health for HIV cure research, to test combinations of novel immunotherapies in clinical trials.
Discoveries at Wistar have led to the creation of vaccines that protect children and adults from widespread, debilitating, and life-threatening diseases and have saved countless lives in the U.S. and abroad:
- Wistar scientists are co-creators of a rotavirus vaccine that was licensed by the Food & Drug Administration in 2016 and is routinely administered in the United States and around the world. The rotavirus vaccine contributes to saving U.S. children from 250,000 emergency room visits and 70,000 hospitalizations each year.
- Two rabies vaccines were developed at Wistar and are used worldwide to prevent rabies-related deaths in humans and wildlife. One is administered as a post-exposure treatment and is nearly 100% effective in preventing fatal rabies infection. It is also given to people at high risk of exposure, including veterinarians and wildlife officers. This vaccine, which was developed at Wistar in the 1960s and ‘70s, has helped to make rabies-related human death a rarity in the U.S. and many other countries. Another Wistar vaccine, licensed in 1995, is used to prevent rabies infection in wildlife.
- A vaccine against rubella (German measles) developed in 1969 at Wistar has been successfully used worldwide since the 1970s and is administered in the U.S. as part of the measles, mumps and rubella (MMR) combination vaccine. The Wistar-developed vaccine led the charge in the eradication of rubella, which was declared eradicated in the U.S. in 2004.
- Wistar contributed technology critical to the development of the first vaccine for the Zika virus approved by the U.S. Food and Drug Administration to be tested in humans.
Education and training
Educating and training the next generation of scientists are central to Wistar's mission. The Institute has developed several programs targeted to all levels of education:
- Postdoctoral program: postdoctoral fellows at Wistar carry out research under the mentorship of one of the faculty members and are offered a well-rounded training program aimed toward successful independent research careers. Funding is available from two different NIH training grants at Wistar and there are several awards for trainee excellence.
- Graduate programs: doctoral training at Wistar can be pursued through the University of Pennsylvania and the Cancer Biology Graduate Program, which is jointly overseen by the University of the Sciences and Wistar.
- Biomedical Technician Training Program: the program, jointly developed by Wistar and Community College of Philadelphia (CCP), is designed to prepare community college students for new career opportunities as research assistants and technicians, combining academic course work at CCP with specialized laboratory training the Institute and other affiliated research institutes.
- Biomedical Research Technician Apprenticeship: this is the first-ever registered, nontraditional apprenticeship program for biomedical research ratified by the Pennsylvania Department of Labor & Industry and offers a high level of specialization and training towards a career pathway to becoming biomedical research technicians in a research laboratory environment.
- High School Fellowship in Biomedical Research: the program provides an opportunity for students to enhance their understanding of current biological/biomedical theory and research tools and techniques. Students are integrated into the daily work of the laboratories, gaining exposure to different facets of research. Mentors help students apply their current knowledge and skills and assist them in making the connection between laboratory experience and their academic studies.
Named after Caspar Wistar, M.D., a well-respected Philadelphia physician, The Wistar Institute is the nation's first independent medical research facility, founded in 1892 by Isaac J. Wistar, great-nephew of Dr. Wistar and a prominent lawyer and Civil War Brigadier General who made a long-lasting contribution to the city of Philadelphia and to biomedical science.
Isaac funded an endowment and a research building for The Wistar Institute of Anatomy and Biology, which would house a large collection of anatomical specimens built by Caspar, who was an outstanding anatomist and paleontologist the author of the first American anatomy textbook. Besides the museum function, Isaac’s vision for The Institute was to initiate "any other work for the increase of original scientific knowledge."
The incorporation of the Institute took place on April 22, 1892 and its first building, designed by Philadelphia architects George W. and William G. Hewitt, was dedicated on May 21, 1894. The Institute is listed in the National Register of Historic Places and is recognized by a historic marker from the Pennsylvania Historical and Museum Commission.
Shortly after the turn of the 20th century, The Wistar Institute began to embody Isaac Wistar’s vision of a center for “new and original research” in the biological and medical sciences. Under the leadership of Milton Greenman, M.D., and Henry Donaldson, Ph.D., the Institute prioritized its research into experimental and investigative biology. Helen Dean King, Ph.D., developed and bred the Wistar rat, the first standardized laboratory animal model from which more than half of all laboratory rats today are thought to be descended. The Institute also gained international recognition as a training ground for young scientists thanks to the scientific journals published by the Wistar Press. Between 1905 and 1925, Wistar scientists published 227 original scientific papers. By 1925, the Institute had solidified its reputation as a center of American biology.
The modern era of scientific discovery at Wistar began under the leadership of virologist and immunologist Hilary Koprowski, M.D., who served as director from 1957 to 1991. During his tenure, the Institute became a leader in vaccine and cancer research. Seminal advancements in cell culture technology were also made at Wistar in that period, with the creation of the WI-38 cell line by Leonard Hayflick, Ph.D., and Paul S. Moorhead, Ph.D. This cell line was used for the development of several vaccines at the Institute and in laboratories around the world.
By the 1970s, Wistar was devoting a major part of its effort and financial resources to cancer research, and in 1972, the Institute earned the designation of National Cancer Institute Cancer Center in basic research. A new Cancer Research building and a vivarium were erected in 1975.
Wistar scientists were among the first to develop antiviral and antitumor monoclonal antibodies that have been widely used as tools for basic research and to develop therapies against cancer and immune diseases. Wistar scientists have been pioneers in the study of oncogenes and the genetic basis of cancer.
The Robert and Penny Fox Research Tower, the latest addition to the Wistar research facility, opened its doors in 2014, adding nearly 90,000 square feet of cutting-edge laboratory space to the Institute and allowing a more integrated style of research that reflects the “team science” discovery approach.
- Helen Dean King, Ph.D., a biologist and the first woman research professor in the country. She was also the first woman scientist at Wistar and was party of the faculty from 1909 until her retirement in 1950. Her research focused on the genetics of inbreeding and sex determination. She was instrumental in the breeding of the Wistar rat, the first standardized laboratory animal model.
- Hilary Koprowski, M.D., a virologist and immunologist, and the inventor of the world's first effective live polio vaccine. He served as director of the Institute from 1957 to 1991 and guided Wistar through an era of international recognition for vaccine development and cancer research. He held the title of Professor Laureate at Wistar and also served on its Board of Trustees.
- Leonard Hayflick, Ph.D., a biologist and expert in aging who worked at Wistar from 1958 to 1968 and discovered that normal human cells divide for a limited number of times in vitro, a phenomenon known as the Hayflick limit. The WI-38 cell strain he developed at the Institute with Paul S. Moorhead, Ph.D., became the substrate for the production of many human virus vaccines.
- David Kritchevsky, Ph.D., an eminent biochemist and expert in human nutrition, who worked at Wistar for five decades starting in 1957. He generated a vast amount of scientific knowledge on the role of lipids in atherosclerosis. He authored the influential textbook Cholesterol, which explored the biologic functions of cholesterol and still is the most comprehensive source of information on this subject.
- Stanley Plotkin, M.D., a physician, who played a pivotal role in discovery of a vaccine against the rubella virus in the 1960s while working at Wistar. Plotkin was a member of Wistar's active research faculty from 1960 to 1991.
- Tadeusz J. Wiktor, D.V.M., a veterinarian and an authority in rabies research. He was part of Wistar’s faculty from 1961 to his death in 1986 and served as the head of the Institute's rabies unit. He was one of the scientists who developed the human vaccine against rabies.
- H. Fred Clark, D.V.M., Ph.D., a veterinarian and vaccine expert and worked at Wistar from 1968 to 1992. He was one of the scientists who developed the rotavirus vaccine.
- Peter C. Doherty, Ph.D., a veterinary surgeon and researcher in the field of medicine, has worked at the Institute from 1975 to 1982 and is currently an emeritus member of the Institute's Board of Trustees. Doherty received the Nobel Prize in Physiology or Medicine jointly with Rolf M. Zinkernagel (1996).
- Carlo Croce, M.D., an oncologist noted for his research into the genetic mechanisms of cancer. During his time at Wistar from 1970 to 1988, he cloned and characterized the B-Cell lymphoma (BCL2) gene and identified chromosomal translocations involved in blood cancer.
- Gerd Maul, Ph.D., an esteemed scientist and electron microscopy expert. He discovered the nuclear dots, structures within the nucleus of mammalian cells that become abundant in response to stress. He worked at Wistar from 1973 to his passing in 2010.
- Ruth Patrick, Ph.D., a botanist and water environment researcher specializing in diatoms and freshwater ecology, who developed ways to measure the health of freshwater ecosystems and established a number of research facilities. Patrick served on Wistar’s Board of Trustees from 1975 through 2008 and remained an emeritus member until her death.
- Giorgio Trinchieri, M.D., an immunologist who worked at Wistar from 1979 to 1999 and served as the chairman of the Immunology Program. While at the Institute, he discovered the cytokine Interleukin-12 (IL-12). He is the director of the Cancer and Inflammation Program at National Cancer Institute’s Center for Cancer Research.
- "Official website of the Wistar Institute". The Wistar Institute. Retrieved 3 July 2009.